METHOD FOR THE PREPARATION OF BINDING MOLECULES

Abstract: This invention comprises a genetically engineered organism displaying the expression product of an inserted gene on its outer surface. In a preferred embodiment, a single chain antibody is displayed on the outer surface of the genetically engineered microorganism.

Description: Method for the Preparation of Binding Kolecules Background of the Invention Field of the Invention The present invention relates to the production of genetically engineered organisms and methods of preparatio of binding molecules. Description of the Background Art In vertebrates, antibody diversity arises from substi tion of hypervariable loops into constant antibody frame¬ works. Each B-cell exhibits its own type of specificity o its surface. When an antigen binds to the surface antibod the B-cell is stimulated to proliferate. Monoclonal antibody production exploits this as follo An animal is injected with a purified antigen. After seve weeks, the spleen is removed from the animal and spleen ce are fused to myeloma cells. This produces hybridoma cells. These cells are plated and screened for binding to antigen. These cells can be grown in tissue culture and will produc quantities of a single antibody—a monoclonal antibody. The gene for the antibody can be recovered and put in microorganisms. Genetic and protein engineering can be altered to obtain better binding, altered specificity. different antigenic behavior than that of the original protein or gene product. Single-chain antibodies (SCA) (copending U.S. Patent Application Serial Nos. 902,971 and 902,970, herein incor¬ porated by reference) are protein molecules which retain t binding domain of antibodies but not the effector domains. SUMMARY OF THE INVENTION In the present invention, a genetically engineered organism is produced which displays on the outer surface o the organism the expression product of a gene which has be inserted. In one embodiment of the invention, a SCA domain (SCA is displayed on the outside of a microorganism while the message for that particular SCA is inside that organism. Description of the Drawings Figure 1, flow chart for production of organisms containing binding molecules on surface. Figure 2 , displaying SCAD on surface. Figure 3, making diverse population of displayed SCAD Figure 4, selecting new SCA specificity. Figure 5, detecting known antigens. Figure 6, lambda assembly. Figure 7, inserting SCAD into V genes. DESCRIPTION OF PREFERRED EMBODIMENTS Any protein or antibody domain for which a gene can b isolated or constructed may be displayed on the outer surf of an organism into which the gene has been inserted. Thi is done by fusing the SCAD gene to the gene coding for a product which normally expresses on the surface of the organism; e.g., an envelope protein. The organism so produced may be easily isolated from organisms which do n contain the desired gene and express the gene product. T organisms may also serve as a solid substrate for the gen product. Prior to the present invention, once an organis which contained a desired gene had been produced, the organisms had to be grown and assayed for the production o the gene product. Then, the gene product had to be isolat purified, and only then was it possible to couple it to a solid substrate. In one embodiment, the organism itself containing the gene product on its outer surface is the so substrate with the desired gene product already attached a may be used as such. The present invention is depicted in general terms in the flow chart on Figure 1. One embodiment shown at step 1000 consists of producing organisms. In this embodiment, microorganism displays a gene product such as a SCAD on th surface of the organism. The next step (step 1010) consis of generating, from the one SCAD displayed and encoded in organism, a diverse population of SCADs by varying the DNA sequence encoding the SCAD by mutation techniques. The ne diverse SCADs generated in step 1010 are displayed on the surface of the organism (step 1020) and organisms are selected based on the surface expressed SCAD which bind to given antigens (step 1030) . The organisms selected in ste 1030 may be used in assays for the given antigen or may be further selected according to the binding or enzymatic characteristics of the gene product expressed on the surfa Once any SCAD has been displayed on the surface of a microorganism, a large population of different SCADs can b generated by in vivo DNA synthesis, step 1010, and each ce or virion can display its own SCAD specificity, step 1020. Antigen binding to the displayed SCAD can be used to selec those microorganisms harboring genes for SCADs which will bind antigen, step 1030. Once a strain of microorganisms selected for antigen binding, it can be used as a sensiti assay for that antigen, step 1040. In step 1050, the abi to refine antigen binding is used to generate novel enzym The steps needed to achieve the construction of a mi organism which displays SCAD are shown in the flow chart Figure 2. In step 2000, a microorganism is selected. In step 2010, a gene within that organism is selected; the g must be one coding for a protein which is displayed on th cell or virion surface. Preferably, the gene should not essential to the organism. In step 2020, the gene for a to some known antigen is introduced into the selected gen and in step 2030, this population of modified genes is pu back into the organism. " In step 2040 the genes are expre sed, and in step 2050 the organisms are selected for bind to immobilized antigen. In step 2060, the gene is sequen to determine which insertion was fruitful. The steps needed to create a diverse population of S displayed on the surface of a microorganism are illustrat in the flow chart on Figure 3. In step 3000, the Combini Determining Regions (CDRs) of the SCA are bounded by rest tion sites. In step 3010, a large variety of DNA sequenc are produced. Each sequence should begin with one of the restriction sequences and end with the corresponding rest tion site. Between these sites should come any constant residues which are included to facilitate placement of restriction sites plus an integral number of triplets. T number of triplets can be varied within the bounds set by 1. Analysis of sequences of natural antibodies wit similar framework; 2. Computer modeling of the framework; 3. Trial and error. In step 3020, these DNA sequences are inserted into the appropriate slots in the SCAD gene. In step 3030, these genes are reinserted into the organism and grown. The organism now contains a diversity of SCA specifications, eac cell displaying its own particular SCAD. In step 3040, this population is passed over the inert support which will be used to support antigen. This step removes those organisms which bind to the inert support even without antigen. In step 4000 in Figure 4, the antigen is attached to an inert support. In step 4010, the population of organisms prepared in steps 3000 to 3040 is passed over the supported antigen. Organisms not binding pass through. In step 4020, the organisms bound to the support are allowed to grow. In step 4030, colonies are found and sampled. In step 4040, the genes of several isolates are sequenced. In step 4050;, the SCAD gene of selected organisms are mutagenized. In step 4060, step 4010 through 4050 are repeated with the muta¬ genized colonies. In step 4060, by washing more stringently, a SCA colony with maximal binding is obtained. Step 4060 can be repeated until suitable binding is obtained. The present invention is also useful for the detection and quantification of known antigens. In step 5000 of Figure 5, a sample with unknown amount of an antigen is attached to an inert support. In step 5010, the strain of organism derived in step 4060 and displaying a SCAD against the antigen is passed over the inert support. In step 5020, the bound organisms are allowed to grow. In step 5030, points of growth are detected, the amount of growth quantitates the amount of antigen. Enzymes, particularly degradative enzymes, work by stabilizing the transition state of a reaction. Chemical theory suggests the shape of the transition states of many reactions. For example, the carbonyl carbons of esters of carboxylic acids are trigonal planar. The transition state for hydrolysis or transesterification is almost certainly tetrahedral. It has recently been demonstrated that a monoclonal antibody against a phosphate ester (which is tetrahedral) is also an esterase. Monoclonal antibody technology has many shortcomings for this task: 1. Slow turnaround 2. Difficulty in refining antibody 3. Inappropriate for highly toxic chemicals 4. Inappropriate for metabolites The method described above can be applied to produce such enzyme-like binding molecules. It will be limited only in the ability to invent antigens which resemble the transi¬ tion states of reactions wished to catalyze. For example, to catalyze the transesterification one can raise a SCA against Having now generally described the invention, the same may further be understood by reference to the following expressly stated. Example 1 The preferred embodiment utilizes the bacteriophage lambda. The gene V of lambda generates a protein which assembles to form the neck of lambda. First gene product (gpV) forms hexameric annuli, then 32 of these annuli stac on the nose cone to form the neck (Figure 6) . Finally, the neck joins the head which contains the DNA. gpV is a protein of molecular weight 3IK. Wild-type lambda have small protuberances on the outside of the neck annuli. Mutants have been isolated in which as much as 13K of gpV is absent. These mutants are viable, though tempera ture sensitive. The mutants are those wherein shortened gp lack the protuberances on the neck annuli. Genetics indi¬ cates that the deletion is from the carboxy end of gene V. SCAs made so far contain the four cysteine residues found in all V H and V 1 domains of natural antibodies. Natural antibodies are secreted and fold in the oxidizing environment of serum. The interior of cells is a reducing environment; thus, one would not expect disulfide bonds to form. The sulfhydryl groups of cysteine lie only 2.0 A apa when a disulfide forms. If the disulfide is reduced, the sulfur atoms should lie 4.0 A apart. Thus, reduced cystein will greatly destabilize folding of a SCA. Therefore, to g proper folding of SCAD inside a cell, one mutates the SCAD gene to change all or some of the CYS's to SER, THR, ALA, o GLY. In one embodiment, the SCA is against bovine growth hormone (BGH) . The V gene of lambda is shown in Figure 7. Genetics indicates that the domain responsible for the warts on the neck lies in the 300 to 400 last base pairs to the right. One cuts the gene at some point in this region, preferably 200 bases from the right end. A random number of bases on either side, up to 200 bases is removed. The SCAD (antiBGH) is inserted and put back into a lysogenic strain of E. coli In the preferred embodiment, the lambda contains a highly beneficial gene for the E. coli. The E. coli is induced. The lambda progeny is passed over a support holding BGH. The E. coli is contacted with the support. The coli should be deficient in a way that th beneficial gene in the lambda will complement. For example the coli could be drug-sensitive and lambda will carry drug resistance. The corresponding antibiotic in the medium put the coli under selective pressure so that only those cells infected by lambda will grow. Only those lambda which boun antigen and stuck to the support are available.

Claims: WE CLAIM: 1. An organism containing a recombinant gene wherei the product of said recombinant gene is presented on the outer surface of said organism, said product also comprisi a single chain antibody domain (SCAD) . 2. The organism of claim 1 wherein the product of s recombinant gene comprises a polypeptide which directs sai SCAD to the surface of said organism. 3. A fusion polypeptide comprising a product normal appearing on the surface of an organism fused to a single chain antibody domain. 4. A method of preparing an organism containing a single chain binding molecule on the outer surface of said organism which comprises: (1) isolating from an organism a first gene encoding for a cell surface protein; (2) inserting a second gene which encodes a sin chain antibody domain into said first gene to form a recom nant fusion gene; and (3) transforming an organism with said recombin fusion gene.

Inventors: BIRD ROBERT E, GLICK J LESLIE, LADNER ROBERT CHARLES, BIRD, ROBERT, E., GLICK, J., LESLIE, LADNER, ROBERT, CHARLES
Applicants: GENEX CORP, GENEX CORPORATION
Application year: 1988
Main classification: C12P21
IPC codes: C07K16, C12N15, C40B40